Wednesday, June 27, 2007

Sankyo Commences Litigation Over Infringement of Benicar HCT Patent

Daiichi Sankyo has commenced litigation on June 22, 2007 against Mylan in the US District Court for the District of New Jersey for infringement of Orange Book listed patent covering olmesartan medoxomil, one of the active ingredients in Sankyo’s antihypertensive drug, Benicar HCT. The lawsuit is pursuant to 35 USC § 271(e) following Mylan submission of Abbreviated New Drug Application (ANDA) with the US FDA seeking marketing approval for generic Benicar HCT prior to expiration of Orange Book listed patent.

No comments:

Post a Comment